

CORRESPONDENCE



Randomized Trial of Hyperimmune Globulin for Congenital CMV Infection — 2-Year Outcomes

TO THE EDITOR: The prevalence of congenital cytomegalovirus (CMV) infection at birth ranges from 0.2 to 2.2% and is higher in low-income communities. Approximately 10% of affected infants are symptomatic at birth, and disability develops in up to 25% by the age of 2 years¹⁻³; sensorineural hearing loss and neurologic impairment are well-recognized sequelae among fetuses infected in early gestation.² There are no in utero treatments recommended in the United States to improve outcomes of pregnancies in persons with primary CMV infection.⁴

We previously reported the results of a multicenter, randomized, placebo-controlled trial of CMV hyperimmune globulin (Cytogam, CSL Behring) involving 399 pregnant women who had primary CMV infection in pregnancy (ClinicalTrials.gov number, NCT01376778). The trial showed no benefit associated with CMV hyperimmune globulin with respect to the incidence of congenital CMV infection or fetal or neonatal death.⁵ Here, we report the results of a planned 2-year follow-up study involving the children of mothers who were enrolled at 17 centers to evaluate whether CMV hyperimmune globulin improves childhood outcomes. The trial protocol

is available with the full text of this letter at NEJM.org. Participants were randomly assigned to receive monthly infusions of CMV hyperimmune globulin or placebo until delivery. After delivery, follow-up of the children was performed by certified research staff for 2 years. Participants and trial personnel were unaware of the treatment assignments throughout follow-up. The outcomes assessed at 24 months (prespecified as secondary trial outcomes) included a composite of death (fetal loss or death during infancy or childhood) or CMV infection with severe disability (defined as sensorineural hearing loss, developmental delay [a cognitive score or motor score of <70 on the Bayley Scales of Infant and Toddler Development, third edition, which is >2 SD below the standardized mean score of 100; higher scores on the scale indicate better performance], chorioretinitis, or seizure disorder from CMV infection); measures of otoacoustic emission; findings on visual reinforcement audiometry; findings on acoustic immittance testing; and cognitive and motor scores on the Bayley Scales of Infant and Toddler Development, third edition (performed by centrally certified examiners).

At least partial data on 2-year outcomes were available for 360 children (90%). Death or CMV infection with severe disability occurred in 20 of the 149 children (13.4%) in the hyperimmune-globulin group and in 15 of the 149 children (10.1%) in the placebo group (relative risk, 1.33; 95% confidence interval, 0.71 to 2.50). No material differences were found between the groups in the incidence of any component of the composite outcome or in any other outcome at 24 months, including severe disability with or without congenital CMV infection (Table 1). No deaths occurred after the delivery hospitalization. Results

THIS WEEK'S LETTERS

- 1822 **Randomized Trial of Hyperimmune Globulin for Congenital CMV Infection — 2-Year Outcomes**
- 1824 **Anti-BNLF2b Screening for Nasopharyngeal Cancer**
- 1825 **Protein-Losing Enteropathy**
- 1826 **Defining the Neurologic Consequences of Preterm Birth**

Table 1. Outcomes among Children at 24 Months.*

Outcome	Hyperimmune Globulin	Placebo	Relative Risk or Difference (95% CI) [†]
Composite outcome: death or CMV infection with severe disability — no./total no. (%)	20/149 (13.4)	15/149 (10.1)	1.33 (0.71 to 2.50)
Death or fetal loss [‡]	10/184 (5.4)	5/176 (2.8)	—
Sensorineural hearing loss, unilateral or bilateral	2/138 (1.4)	7/146 (4.8)	—
Chorioretinitis	0/173 (0)	1/171 (0.6)	—
Seizure disorder	2/173 (1.2)	0/171 (0)	—
Bayley-III cognitive score of <70	4/155 (2.6)	4/160 (2.5)	—
Bayley-III motor score of <70	6/155 (3.9)	1/158 (0.6)	—
Overall status — no./total no. (%)			
Death or fetal loss [§]	10/148 (6.8)	5/149 (3.4)	—
Congenital CMV infection with severe disability	6/148 (4.1)	7/149 (4.7)	—
Congenital CMV infection without severe disability	21/148 (14.2)	19/149 (12.8)	—
Not infected with CMV with severe disability	4/148 (2.7)	3/149 (2.0)	—
Not infected with CMV with no disabilities	107/148 (72.3)	115/149 (77.2)	—
Other outcomes			
Bayley-III cognitive score	96.2±15.1	97.1±13.5	-0.9 (-4.1 to 2.3)
Bayley-III motor score	98.7±16.4	101.9±14.9	-3.2 (-6.7 to 0.3)
Birth weight <10th percentile — no./total no. (%)	20/169 (11.8)	21/167 (12.6)	0.94 (0.53 to 1.67)

* Plus-minus data are means ±SD. Severe disability was defined as any sensorineural hearing loss, developmental delay (a cognitive or motor score of less than 70 on the Bayley Scales of Infant and Toddler Development, third edition [Bayley-III]), which is >2 SD below the standardized mean score of 100; higher scores on the scale indicate better performance), chorioretinitis, or seizure disorder.

[†] Relative risk is provided for the composite outcome and for <10th percentile weight, and the between-group difference is provided for the mean Bayley-III scores. The widths of the confidence intervals have not been adjusted for multiplicity and should not be used for hypothesis testing.

[‡] No deaths occurred after the delivery hospitalization.

[§] Data from the cohort of participants with information on death or fetal loss plus information on CMV infection and disability status are included here.

obtained by multiple imputation were consistent with those in the complete case analysis (Table S2 in the Supplementary Appendix, available with the full text of this letter at NEJM.org). Limitations of this study include low event rates and missing data.

In this multicenter trial, CMV hyperimmune globulin did not improve 2-year hearing or developmental outcomes. These results, along with those previously reported, do not support the use of maternal CMV hyperimmune globulin to improve outcomes in the children of women with primary CMV infection in early pregnancy.

Brenna L. Hughes, M.D.

Brown University
Providence, RI
brenna.hughes@duke.edu

Rebecca G. Clifton, Ph.D.

George Washington University
Washington, DC

Dwight J. Rouse, M.D.

Brown University
Providence, RI

George R. Saade, M.D.

University of Texas Medical Branch
Galveston, TX

Mara J. Dinsmoor, M.D., M.P.H.

Northwestern University
Chicago, IL

Uma M. Reddy, M.D., M.P.H.

Eunice Kennedy Shriver National Institute of Child Health
and Human Development
Bethesda, MD

Robert Pass, M.D.

University of Alabama at Birmingham
Birmingham, AL

Donna Allard, R.N.

Brown University
Providence, RI

Gail Mallett, R.N.

Northwestern University
Chicago, IL

Cora MacPherson, Ph.D.

George Washington University
Washington, DC

Ronald Wapner, M.D.

Columbia University
New York, NY

Torri Metz, M.D.

University of Utah Health Sciences Center
Salt Lake City, UT

William H. Goodnight, M.D.

University of North Carolina at Chapel Hill
Chapel Hill, NC

Alan T.N. Tita, M.D., Ph.D.

University of Alabama at Birmingham
Birmingham, AL

Maged M. Costantine, M.D.

Ohio State University
Columbus, OH

Geeta K. Swamy, M.D.

Duke University
Durham, NC

Kent D. Heyborne, M.D.

University of Colorado School of Medicine, Anschutz Medical
Campus
Aurora, CO

Edward K. Chien, M.D.

Case Western Reserve University
Cleveland, OH

Suneet P. Chauhan, M.D.

University of Texas Health Science Center at Houston
Houston, TX

Yasser Y. El-Sayed, M.D.

Stanford University
Stanford, CA

Brian M. Casey, M.D.

University of Texas Southwestern Medical Center
Dallas, TX

Samuel Parry, M.D.

University of Pennsylvania
Philadelphia, PA

Hyagriv N. Simhan, M.D.

University of Pittsburgh
Pittsburgh, PA

Peter G. Napolitano, M.D.

Madigan Army Medical Center
Joint Base Lewis–McChord, WA

George A. Macones, M.D.

Washington University
Saint Louis, MO

for the Eunice Kennedy Shriver National Institute
of Child Health and Human Development
Maternal–Fetal Medicine Units Network*

*A list of the members of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal–Fetal Medicine Units Network is provided in the Supplementary Appendix, available at NEJM.org.

The content of this article does not necessarily reflect the views or policies of the National Institutes of Health, the Department of the Army, the Department of Defense, or the U.S. government. The investigators have adhered to the policies for protection of human subjects as prescribed in 45 CFR 46.

Presented in part at the 2022 Annual Meeting of the Society for Maternal Fetal Medicine.

Supported by grants from the NICHD (HD40500, HD36801, HD53097, HD40512, HD40485, HD34208, HD40560, HD27869, HD27915, HD68258, HD68282, HD40544, HD40545, HD68268, HD34116, HD87192, HD87230) and the National Center for Advancing Translational Sciences (UL1TR001873 and UL1TR000040). CSL Behring provided the Cytogam and AlbuRx but had no other role in the trial.

Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.

The data set will be made available through the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Data and Specimen Hub (<https://dash.nichd.nih.gov/>).

1. Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. *N Engl J Med* 1992;326:663-7.
2. Pass RF, Fowler KB, Boppana SB, Britt WJ, Stagno S. Congenital cytomegalovirus infection following first trimester maternal infection: symptoms at birth and outcome. *J Clin Virol* 2006;35:216-20.
3. Stagno S, Pass RF, Dworsky ME, Alford CA Jr. Maternal cytomegalovirus infection and perinatal transmission. *Clin Obstet Gynecol* 1982;25:563-76.
4. Practice bulletin no. 151: cytomegalovirus, parvovirus B19, varicella zoster, and toxoplasmosis in pregnancy. *Obstet Gynecol* 2015;125:1510-25.
5. Hughes BL, Clifton RG, Rouse DJ, et al. A trial of hyperimmune globulin to prevent congenital cytomegalovirus infection. *N Engl J Med* 2021;385:436-44.

DOI: 10.1056/NEJMc2308286

Anti-BNLF2b Screening for Nasopharyngeal Cancer

TO THE EDITOR: In their article on screening for Epstein–Barr virus DNA or antibodies in the diagnosis of nasopharyngeal carcinoma, Li and colleagues (Aug. 31 issue)¹ describe a promising biomarker. Notwithstanding, I note that the number needed to screen to detect one case of nasopharyngeal carcinoma is approximately 540.

Here, we estimate the number needed to screen to prevent one death, with several assumptions made. In a major hospital in Zhongshan, where this study was performed, the 5-year overall survival of patients with treated nasopharyngeal carcinoma is 80.5%.² This percentage translates to screening 920 patients to prevent one death,